Company News - Press Releases - Events - Publications

GENFIT: Leader of a €2.7 M European-funded EUROTRANSBIO program

Press Release of Bicoll’s OLNORME II partner Genfit SA

The OLNORME II Consortium, for which GENFIT is the leader, is focused on the development of a new class of drug candidates for the prevention and treatment of cardiometabolic diseases with an inflammatory component.
LILLE, France, and CAMBRIDGE, Mass., December 20th, 2010
GENFIT (Alternext: ALGFT; ISIN:FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, will receive €1.2 M as part of the EuroTransBio funding initiative.

Press release of GENFIT, Olnorme II

Questions? Get in touch!

We would love talking to you:

Bicoll GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
+49 (0)89 820 106 30

This Site uses cookies, which could include third-party cookies, to ensure its technical functioning and which may contain tracking information about visitors. By continuing to browse this site you agree to our use of cookies. If you want to learn more about our Privacy Policy click here.